<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04735393</url>
  </required_header>
  <id_info>
    <org_study_id>ADX-102-DED-021</org_study_id>
    <nct_id>NCT04735393</nct_id>
  </id_info>
  <brief_title>A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease</brief_title>
  <official_title>A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of 0.25% Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aldeyra Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aldeyra Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial&#xD;
      Evaluating the Safety of 0.25% Reproxalap Ophthalmic Solution in Subjects with Dry Eye&#xD;
      Disease&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Safety assessment period (Day 1 through Day 28 or Day 1 through Day 360)</time_frame>
    <description>Percentages of subjects with ocular treatment-emergent adverse events (TEAEs).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">525</enrollment>
  <condition>Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>Reproxalap Ophthalmic Solution (0.25%) QID for four weeks followed by BID for two weeks.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Ophthalmic Solution QID for four weeks followed by BID for two weeks.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Reproxalap Ophthalmic Solution (0.25%) QID for four weeks followed by BID for 11 months.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Ophthalmic Solution QID for four weeks followed by BID for 11 months.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reproxalap Ophthalmic Solution (0.25%)</intervention_name>
    <description>Reproxalap Ophthalmic Solution (0.25%) administered for six weeks (QID for four weeks then BID for two weeks).</description>
    <arm_group_label>Reproxalap Ophthalmic Solution (0.25%) QID for four weeks followed by BID for two weeks.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Vehicle Ophthalmic Solution administered for six weeks (QID for four weeks then BID for two weeks).</description>
    <arm_group_label>Vehicle Ophthalmic Solution QID for four weeks followed by BID for two weeks.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reproxalap Ophthalmic Solution (0.25%)</intervention_name>
    <description>Reproxalap Ophthalmic Solution (0.25%) administered for one year (QID for four weeks then BID for 11 months).</description>
    <arm_group_label>Reproxalap Ophthalmic Solution (0.25%) QID for four weeks followed by BID for 11 months.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Vehicle Ophthalmic Solution administered for one year (QID for four weeks then BID for 11 months).</description>
    <arm_group_label>Vehicle Ophthalmic Solution QID for four weeks followed by BID for 11 months.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age (either gender and any race);&#xD;
&#xD;
          -  Reported history of dry eye for at least 6 months prior to Visit 1;&#xD;
&#xD;
          -  History of use or desire to use eye drops for dry eye symptoms within 6 months of&#xD;
             Visit 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant slit lamp findings at Visit 1 that may include active&#xD;
             blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation, or active&#xD;
             ocular allergies that require therapeutic treatment, and/or in the opinion of the&#xD;
             investigator may interfere with study parameters;&#xD;
&#xD;
          -  Diagnosis of an ongoing ocular infection (bacterial, viral, or fungal), or active&#xD;
             ocular inflammation at Visit 1;&#xD;
&#xD;
          -  Contact lens use within 7 days of Visit 1 or anticipate using contact lenses during&#xD;
             the trial;&#xD;
&#xD;
          -  Eye drop use within 2 hours of Visit 1;&#xD;
&#xD;
          -  Previous laser-assisted in situ keratomileusis (LASIK) surgery within the last 12&#xD;
             months;&#xD;
&#xD;
          -  Cyclosporine 0.05% or 0.09% or lifitegrast 5.0% ophthalmic solution within 90 days of&#xD;
             Visit 1;&#xD;
&#xD;
          -  Planned ocular and/or lid surgeries over the study period or any ocular surgery within&#xD;
             6 months of Visit 1;&#xD;
&#xD;
          -  Temporary punctal plugs during the study that have not been stable within 30 days of&#xD;
             Visit 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bill Cavanagh</last_name>
    <phone>781-257-3063</phone>
    <email>bcavanagh@aldeyra.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Torkildsen, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

